downloadCannabics Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and production of proprietary technologies for treating a wide range of indications through medical cannabis.

The flagship product of Cannabics is the Cannabics SR capsule, a sustained release capsule that provides palliative care to patients suffering from certain types of cancer. The Cannabics SR capsule uses a patented formulation and contains cannabinoids pure concentrate. Cannabinoids are extracted from various strains of the cannabis plant selected and bred by the company. Each capsule provides 10 to 12 hours of therapeutic effects, which allows for once-per-day dosage.

Cannabics Pharmaceuticals, Inc. also supplies other products in the company line, including the condensed Cannabis VP pill for standard vaporizers, and the capsule Cannabics IN for dry powder inhalers. As of 2013, the products of the company have circulated through five hospitals in Israel, where medical marijuana use is permitted for cancer patients and for treatment for pain-related illnesses.

Cannabics Pharmaceuticals, Inc., through its research and development extension in Israel, is developing a pipeline of advanced cannabinoid-based therapies. With the company’s collaboration with major medical centers in the U.S., Israel, and Europe, Cannabics is now launching clinical studies investigating the beneficial effects of their products in a wide range of medical indications.

Cannabics Pharmaceuticals, Inc. is a subsidiary of Cannabics, Inc., and was founded in 2012 by research experts in the fields of molecular biology, cancer research, and pharmacology.  The company, which is based in Bethseda, Maryland, was known as Thrust Energy Corp until 2011, and as American Mining Corporation until June in 2014.

Cannabics Pharmaceuticals, Inc. is traded in the OTC Markets under the stock symbol CNBX. The company’s key executives are Dr. Zohar Koren, CEO and Co-founder; Dr. Eyal Ballan, CTO and Co-founder; and Itamar Borochov, Marketing VP.

Yahoo! Finance: CNBX News

Latest Financial News for CNBX

OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ --  OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...

SodaStream CEO Daniel Birnbaum to Join Seedo Board

Seedo Corp. is an agro-tech company providing the world's first fully automated and controlled indoor growing machine for pesticide-free agricultural and vertical farming markets. Cannabics owns approximately 20% of Seedo Corp.'s issued and outstanding common stock.

Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases, to form a equally owned joint venture (JV) which will focus on the research and development of cannabinoid based treatments for ophthalmic disorders.

Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

Companies Will Launch New Entity to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions HOD HASHARON, Israel , March 6 , 2019  /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" ...

Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids

Cannabics has submitted a protocol for the Helsinki Committee to conduct a nationwide study on fresh biopsies treated with a multitude of cannabinoid compounds and chemotherapies TEL AVIV, Israel and BETHESDA, ...